var data={"title":"Albendazole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Albendazole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5575?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">see &quot;Albendazole: Drug information&quot;</a> and <a href=\"topic.htm?path=albendazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Albendazole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130833\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Albenza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044931\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anthelmintic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044925\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">see &quot;Albendazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neurocysticercosis (<i>Taenia solium,</i> pork tapeworm):</b> Children and Adolescents: <b>Note:</b> Patients should receive concurrent corticosteroid for the first week of albendazole therapy and anticonvulsant therapy as required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;60 kg: Oral: 7.5 mg/kg/dose twice daily for 8 to 30 days; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;60 kg: Oral: 400 mg twice daily for 8 to 30 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hydatid disease (<i>Echinococcus granulosus</i>, dog tapeworm<i>)</i>: </b>Children and Adolescents (WHO 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;60 kg: Oral: 7.5 mg/kg/dose twice daily; maximum dose: 400 mg/dose; 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;60 kg: Oral: 400 mg twice daily; 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Ancyclostoma caninum </i></b>\n      <b>(Eosinophilic enterocolitis):</b>Limited data available: Children and Adolescents: Oral: 400 mg as a single dose (Medical Letter [Parasitic infections 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Ancylostoma duodenale</i></b>\n      <b> or <i>Necator americanus</i> (hookworms):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months: Very limited data available: Oral: 200 mg as a single dose. Dosing based on two cases (patient #1: age: 12 weeks, weight: 4.2 kg; and patient #2: age: 8 months, weight: 5.8 kg) of exclusively breastfed infants who showed clinical improvement after single-dose albendazole therapy (Bhatia 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;2 years: Limited data available: Oral: 200 mg as a single dose; may repeat in 3 weeks (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;2 years and Adolescents: Limited data available: Oral: 400 mg as a single dose; may repeat in 3 weeks (CDC; Medical Letter [Parasitic infections 2013]; WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ascariasis (intestinal roundworm)</b>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;2 years: Oral: 200 mg as a single dose; may repeat in 3 weeks (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;2 years and Adolescents: Oral: 400 mg as a single dose; may repeat in 3 weeks (CDC; Medical Letter [Parasitic infections 2013]; WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Baylisascaris procyonis </i></b>\n      <b>(raccoon roundworm), postexposure prophylaxis andtreatment</b>\n      <b>:</b> Limited data available: Children and Adolescents: Oral: Frequently reported dose: 40 mg/kg/day (range: 20 to 50 mg/kg/day) in a single or two divided doses <b>or</b> 400 mg twice daily. Initiate as soon as possible after potential exposure (ideally within 3 days) to prevent clinical disease in any child at risk (eg, ingestion of raccoon stool or contaminated soil). Duration for prophylaxis is at least 10 days. Reported treatment duration is usually 4 weeks (Gavin 2002; Graeff-Teixeira 2016; Hajek 2009; Murray 2004; Pai 2007; Park 2000; Peters 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Capillariasis:</b> Limited data available: Children and Adolescents: Oral: 400 mg once daily for at least 10 days (CDC; Medical Letter [Parasitic infections 2013]; Sawamura 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Clonorchis sinensis</i></b>\n      <b> (Chinese liver fluke):</b> Limited data available: Children and Adolescents: Oral: 10 mg/kg/dose once daily for 7 days (CDC; Medical Letter [Parasitic infections 2013]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cutaneous larva migrans (dog and cat hookworm):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;8 months and Children &le;10 kg: Very limited data available: Oral: 200 mg once daily for 3 days. Dosing based on four cases (ages 8, 11, 12, and 13 months) of infants who showed clinical improvement after therapy. There was complete resolution of infection in two of these infants; one infant had initial improvement, then recurrence requiring a second course of therapy and eventually alternate therapy, and another infant had resolution of symptoms followed by appearance of a similar lesion at a different location 3 months later, received a second course, and had rapid resolution of all symptoms (Black 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children weighing &gt;10 kg and Adolescents: Limited data available: Oral: 400 mg once daily for 3 days (Medical Letter [Parasitic infections 2013]; WHO 2010); some patients may only need a single dose (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Enterobiasis</b>\n      <b> (pinworm)</b>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;2 years: Oral: 200 mg as a single dose; may repeat in 3 weeks (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;2 years and Adolescents: Oral: 400 mg as a single dose; may repeat in 2 to 3 weeks (Medical Letter [Parasitic infections 2013]; WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Filariasis (<i>Wuchereria Bancroft);</i><i></i>microfilaria, reduction or suppression or community eradication programs:</b> Limited data available. Administer in combination with either ivermectin or diethylcarbamazine. <b>Note:</b> Does not kill all the adult worms (Medical Letter [Parasitic infections 2013]; WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;10 kg: Oral: 200 mg once annually for 5 years</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;10 kg and Adolescents: Oral: 400 mg once annually for 5 years</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Giardiasis <i>(Giardia duodenalis)</i>:</b> Limited data available: Children &ge;2 years and Adolescents: Oral: 10 mg/kg/day once daily for 5 days; maximum dose: 400 mg/dose or 400 mg once daily for 5 days (Escobedo 2016, Medical Letter [Parasitic infections 2013]; Yereli 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Microsporidia</i></b>\n      <b> infection (except <i>Enterocytozoon sp.</i> and <i>V. corneae</i>)</b>: Limited data available: Children and Adolescents: Oral: 7.5 mg/kg/dose twice daily; maximum dose: 400 mg/dose (HHS [pediatric 2016]; Medical Letter [Parasitic infections 2013]) in HIV-exposed/-positive, continue until resolution of signs and symptoms and sustained immune reconstitution (&gt;6 months at CDC immunologic category 1 or 2) after ART initiation (HHS [pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Strongyloidiasis (<i>Strongyloides stercoralis</i>):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;10 kg: Oral: 200 mg once daily for 3 days; may repeat course in 3 weeks (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;10 kg and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CDC recommendations: Oral: 400 mg twice daily for 7 days (CDC)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">WHO recommendations: Oral: 400 mg once daily for 3 days; may repeat course in 3 weeks (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichinellosis (<i>Trichinosis</i>):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CDC recommendations: Children and Adolescents: Oral: 400 mg twice daily for 8 to 14 days (CDC; Medical Letter [Parasitic infections 2013])</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">WHO recommendations: Children &gt;10 kg and Adolescents: Oral: 400 mg once daily for 8 to 14 days (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichuriasis (whipworm): </b>Limited data available: Children &gt;2 years and Adolescents: Oral: 400 mg once daily for 3 days (Medical Letter [Parasitic infections 2013]; WHO 2010); mild cases may be treated with a single dose of 200 to 400 mg; may repeat course in 3 weeks (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Toxocariasis (ocular larva migrans, visceral larva migrans): </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CDC recommendations:<b></b>Children and Adolescents: Oral: 400 mg twice daily for 5 days (CDC; Medical Letter [Parasitic infections 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">WHO recommendation: Children and Adolescents: Oral: 10 mg/kg/dose once daily for 5 days; maximum dose: 400 mg/dose (WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hydatid </b>\n      <b>\n        <i>(Echinococcus granulosus)</i></b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;60 kg: Oral: 7.5 mg/kg/dose twice daily; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;60 kg: Oral: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Administer dose for three 28-day cycles with a 14-day drug-free interval in between each cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neurocysticercosis </b>\n      <b>\n        <i>(Taenia solium)</i></b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;60 kg: Oral: 7.5 mg/kg/dose twice daily for 8 to 30 days; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;60 kg: Oral: 400 mg twice daily for 8 to 30 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Give concurrent anticonvulsant and corticosteroid therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in renal impairment</b>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, the need for adjustment not likely since albendazole is primarily eliminated by hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment</b>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130812\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albenza: 200 mg [contains saccharin sodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130799\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044934\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food. For patients who have difficulty swallowing whole tablets, tablet may be crushed or chewed and swallowed with a drink of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5266184\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 20&deg;C and 25&deg;C (68&deg;F to 77&deg;F)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044933\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of <i>Taenia solium</i> (pork tapeworm) and treatment of cystic hydatid disease of the liver, lung, and peritoneum caused by the larval form of <i>Echinococcus granulosus</i> (dog tapeworm) (FDA approved in pediatric patients (age not specified) and adults); has also been used in the treatment of <i>Ancylostoma caninum</i>, <i>Ancylostoma duodenale </i>(hookworm), Ascariasis (intestinal roundworm), <i>Baylisascaris procyonis </i>(raccoon roundworm), Capillariasis, <i>Clonorchis sinensis</i> (Chinese liver fluke), cutaneous larva migrans, Enterobiasis (pinworm), Filariasis (<i>Wuchereria Bancroft)</i>, Giardiasis, <i>Gnathostoma spinigerum</i>, <i>Gongylonema</i> sp: microsporidiosis, <i>Necator americanus</i> (hookworm), <i>Oesophagostomum bifurcum, <i>Opisthorchis viverrini </i></i>(liver fluke), <i>Strongyloides stercoralis</i>, Trichinellosis (Trichinosis), Trichostrongyliasis (hairworm), <i>Trichuris trichiura</i> (whipworm), and Toxocariasis (ocular larva migrans, visceral larva migrans)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3195081\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Albenza may be confused with Aplenzin, Relenza</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Albenza [US] may be confused with Avanza brand name for mirtazapine [Australia]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130871\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Central nervous system: Headache (more common in neurocysticercosis) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hepatic: Increased liver enzymes (more common in hydatid) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Central nervous system: Dizziness, increased intracranial pressure, meningism, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Dermatologic: Alopecia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Gastrointestinal: Abdominal pain, nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute hepatic failure, acute renal failure, agranulocytosis, aplastic anemia, erythema multiforme, granulocytopenia, hepatitis, hypersensitivity reaction, leukopenia, neutropenia, pancytopenia, skin rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130817\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to albendazole, benzimidazoles, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130803\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, and pancytopenia have occurred leading to fatalities (rare); use with caution in patients with hepatic impairment (more susceptible to hematologic toxicity).  Discontinue therapy in all patients who develop clinically significant decreases in blood cell counts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transaminase elevations: Reversible elevations in hepatic enzymes have been reported. Patients with abnormal LFTs and hepatic echinococcosis are at an increased risk of hepatotoxicity. Discontinue therapy if LFT elevations are &gt;2 times the upper limit of normal; may consider restarting treatment (with frequent monitoring of LFTs) when hepatic enzymes return to pretreatment values. Discontinue therapy if hepatic enzymes are significantly increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurocysticercosis: Appropriate use: Corticosteroids should be administered before or upon initiation of albendazole therapy to minimize inflammatory reactions and prevent increased intracranial pressure. Anticonvulsant therapy should be used concurrently to prevent seizures. If retinal lesions exist, weigh risk of further retinal damage due to albendazole-induced inflammatory changes to the retinal lesion vs benefit of disease treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130860\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130807\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13269&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease serum concentrations of the active metabolite(s) of Albendazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase serum concentrations of the active metabolite(s) of Albendazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease serum concentrations of the active metabolite(s) of Albendazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease serum concentrations of the active metabolite(s) of Albendazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130829\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Albendazole serum levels may be increased if taken with a fatty meal (increases the oral bioavailability by up to 5 times). Management: Should be administered with a high-fat meal when treating systemic infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130808\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130820\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Albendazole should not be used during pregnancy, if at all possible. The manufacturer recommends a pregnancy test prior to therapy in women of reproductive potential. Women should be advised to avoid pregnancy during and for at least 1 month following therapy. Discontinue if pregnancy occurs during treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044930\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor liver function tests and CBC at start of each cycle and every 2 weeks during therapy (more frequent monitoring for patients with liver disease), fecal specimens for ova and parasites; pregnancy test; ophthalmic exam for retinal lesions (patients with neurocysticercosis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130802\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Active metabolite, albendazole sulfoxide, causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired, and desecratory substances accumulate intracellulary. ATP production decreases causing energy depletion, immobilization, and worm death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130816\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> In pediatric patients (6-13 years), pharmacokinetic values were reported to be similar to adult data.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Poor from the GI tract; may increase up to 5 times when administered with a fatty meal </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed throughout the body including urine, bile, liver, cyst wall, cyst fluid, and CSF  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 70% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; extensive first-pass effect; pathways include rapid sulfoxidation to active metabolite (albendazole sulfoxide [major]), hydrolysis, and oxidation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 8 to 12 hours (albendazole sulfoxide) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 5 hours for the metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1% as active metabolite); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130819\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Albenza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (2): $438.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130822\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abentel (BD, CN, TH);</li>\n      <li>ABZ (IN, ZW);</li>\n      <li>Acure (PK);</li>\n      <li>Adazol (EC);</li>\n      <li>Albatel (TH);</li>\n      <li>Alben (BR);</li>\n      <li>Alben-VC (TH);</li>\n      <li>Albenda (AE, BH, KW, LB, QA, SA);</li>\n      <li>Albentel (PE);</li>\n      <li>Albentox (LK);</li>\n      <li>Albenzol (EC);</li>\n      <li>Albex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LK, LY, OM, QA, SA, SY, VN, YE);</li>\n      <li>Albezole (IN);</li>\n      <li>Albi (KR);</li>\n      <li>Aldaben (BD);</li>\n      <li>Aldazol (PH);</li>\n      <li>Alfuca (TH);</li>\n      <li>Allbacom (KR);</li>\n      <li>Almex (MY);</li>\n      <li>Alminth (IN);</li>\n      <li>Alzental (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);</li>\n      <li>Alzol (TH);</li>\n      <li>Andazol (TR);</li>\n      <li>Anhelmin (UA);</li>\n      <li>Ascarol (EC);</li>\n      <li>Ben A (BD);</li>\n      <li>Bendex (ET);</li>\n      <li>Bendex-400 (ZA);</li>\n      <li>Benzol (PH);</li>\n      <li>Bruzol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Buxol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>CB-400 (TH);</li>\n      <li>Ceprazol (CL);</li>\n      <li>Ciclopar (CO);</li>\n      <li>Cystazole (JO);</li>\n      <li>Dalben (HR);</li>\n      <li>Daxol Plus (PY);</li>\n      <li>Dazole (LK);</li>\n      <li>Digezanol (MX);</li>\n      <li>Emanthal (IN);</li>\n      <li>Eskasole (MX);</li>\n      <li>Eskazole (AT, AU, DE, ES, GB, IL, JP, NL, NZ);</li>\n      <li>Estazole (LK);</li>\n      <li>Fintel (PE);</li>\n      <li>Frantel (VN);</li>\n      <li>Gascop (MX);</li>\n      <li>Gloalbendazole (KR);</li>\n      <li>Helmiben (UY);</li>\n      <li>Helmidazole (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Hyemex (PH);</li>\n      <li>Labenda (TH);</li>\n      <li>Lokaben (LK);</li>\n      <li>Lomsin (MX);</li>\n      <li>Lurdex (MX);</li>\n      <li>Mebenix (BR);</li>\n      <li>Nemozole (IN, ZW);</li>\n      <li>Olworm (LK);</li>\n      <li>Ovis (ET);</li>\n      <li>Oxal (MX);</li>\n      <li>Oxarmin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Pantex (PY);</li>\n      <li>Paranthil (ZA);</li>\n      <li>Parhel (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Rex (KR);</li>\n      <li>Rotopar (EC);</li>\n      <li>Sintel (BD);</li>\n      <li>Sioban (IN);</li>\n      <li>Temizol (PY);</li>\n      <li>Thelban (MY);</li>\n      <li>Unizol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Valbazen Vet (NO);</li>\n      <li>Vastus (AR);</li>\n      <li>Vemizol (MY);</li>\n      <li>Vermin Plus (MX);</li>\n      <li>Vetoben (TH);</li>\n      <li>Vormil (UA);</li>\n      <li>Wormed (ZW);</li>\n      <li>Zeben (TH);</li>\n      <li>Zela (TH);</li>\n      <li>Zendal (MY);</li>\n      <li>Zental (RO);</li>\n      <li>Zentel (AE, AU, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CY, CZ, EC, EG, ET, FR, GH, GM, GN, GR, GT, GY, HN, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, OM, PA, PE, PL, PR, PT, QA, SA, SC, SD, SG, SI, SK, SL, SN, SR, SV, SY, TH, TN, TT, TZ, UA, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Zestaval (TR, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdel-tawab AM, Bradley M, Ghazaly EA, et al, &quot;Albendazole and its Metabolites in the Breast Milk of Lactating Women Following a Single Oral Dose of Albendazole,&quot;<i> Br J Clin Pharmacol</i>, 2009, 68(5):737-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/19916998/pubmed\" target=\"_blank\" id=\"19916998\">19916998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albenza tablets (albendazole) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baranwal AK, Singhi PD, Khandelwal N, et al, &ldquo;Albendazole Therapy in Children With Focal Seizures and Single Small Enhancing Computerized Tomographic Lesions: A Randomized, Placebo-Controlled, Double Blind Trial,&rdquo; <i>Pediatr Infect Dis J</i>, 1998, 17(8):696-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/9726343/pubmed\" target=\"_blank\" id=\"9726343\">9726343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatia V, Das MK, Kumar P, Arora NK. Infantile hookworm disease. <i>Indian Pediatr</i>. 2010;47(2):190-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/20228435/pubmed\" target=\"_blank\" id=\"20228435\">20228435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Black MD, Grove DI, Butcher AR, Warren LJ. Cutaneous larva migrans in infants in the Adelaide Hills. <i>Australas J Dermatol</i>. 2010;51(4):281-284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/21198527/pubmed\" target=\"_blank\" id=\"21198527\">21198527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC) parasite website. Available at <a href=\"https://www.cdc.gov/parasites/index.html\" target=\"_blank\">https://www.cdc.gov/parasites/index.html</a>. Date accessed was 11/11/2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Parasitic Infections,&rdquo; <i>Med Lett Drugs Ther</i>, 2013, 11(suppl):e1-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gavin PJ, Kazacos KR, Tan TQ, et al. Neural larva migrans caused by the raccoon roundworm Baylisascaris procyonis. <i>Pediatr Infect Dis J</i>. 2002;21(10):971-975.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/26960940/pubmed\" target=\"_blank\" id=\"26960940\">26960940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graeff-Teixeira C, Morassutti AL, Kazacos KR. Update on Baylisascariasis, a Highly Pathogenic Zoonotic Infection. <i>Clin Microbiol Rev</i>. 2016;29(2):375-399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/12394823/pubmed\" target=\"_blank\" id=\"12394823\">12394823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hajek J, Yau Y, Kertes P, et al. A child with raccoon roundworm meningoencephalitis: A pathogen emerging in your own backyard? <i>Can J Infect Dis Med Microbiol</i>. 2009;20(4):e177-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/12394823/pubmed\" target=\"_blank\" id=\"12394823\">12394823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. December 2016. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jung H, Sanchez M, Gonzalez-Astiazaran A, et al, &ldquo;Clinical Pharmacokinetics of Albendazole in Children With Neurocysticercosis,&rdquo; <i>Am J Ther</i>, 1997, 4(1):23-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/10423586/pubmed\" target=\"_blank\" id=\"10423586\">10423586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray WJ, Kazacos KR. Raccoon roundworm encephalitis. <i>Clin Infect Dis</i>. 2004;39(10):1484-1492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/15546085/pubmed\" target=\"_blank\" id=\"15546085\">15546085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pai PJ, Blackburn BG, Kazacos KR, Warrier RP, B&eacute;gu&eacute; RE. Full recovery from Baylisascaris procyonis eosinophilic meningitis. <i>Emerg Infect Dis</i>. 2007;13(6):928-930.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/17553240/pubmed\" target=\"_blank\" id=\"17553240\">17553240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park SY, Glaser C, Murray WJ, et al. Raccoon roundworm (Baylisascaris procyonis) encephalitis: case report and field investigation. <i>Pediatrics</i>. 2000;106(4):E56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/11015551/pubmed\" target=\"_blank\" id=\"11015551\">11015551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paul I, Gnanamani G, and Nallam NR, &ldquo;Intestinal Helminth Infections Among School Children in Visakhapatnam,&rdquo; <i>Indian J Pediatr</i>, 1999, 66(5):669-73.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pengsaa K, Sirivichayakul C, Pojjaroen-anant C, et al, &ldquo;Albendazole Treatment for <i>Giardia intestinalis</i> Infections in School Children,&rdquo; <i>Southeast Asian J Trop Med Public Health</i>, 1999, 30(1):78-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/10695793/pubmed\" target=\"_blank\" id=\"10695793\">10695793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peters JM, Madhavan VL, Kazacos KR, Husson RN, Dangoudoubiyam S, Soul JS. Good outcome with early empiric treatment of neural larva migrans due to Baylisascaris procyonis. <i>Pediatrics</i>. 2012;129(3):e806-811.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/22311989/pubmed\" target=\"_blank\" id=\"22311989\">22311989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sawamura R, Fernandes MI, Peres LC, et al. Hepatic capillariasis in children: report of 3 cases in Brazil. <i>Am J Trop Med Hyg</i>. 1999;61(4):642-647.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/10548302/pubmed\" target=\"_blank\" id=\"10548302\">10548302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &quot;WHO Model Formulary for Children,&quot; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yereli K, Balcio&#287;lu IC, Ertan P, et al, &quot;Albendazole as an Alternative Therapeutic Agent for Childhood Giardiasis in Turkey,&quot; <i>Clin Microbiol Infect</i>, 2004, 10(6):527-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albendazole-pediatric-drug-information/abstract-text/15191380/pubmed\" target=\"_blank\" id=\"15191380\">15191380</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13269 Version 96.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130833\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1044931\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1044925\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130812\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F130799\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1044934\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F5266184\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1044933\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3195081\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130871\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130817\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130803\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F130860\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130807\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F130829\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F130808\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130820\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1044930\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130802\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F130816\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F130819\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130822\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13269|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">Albendazole: Drug information</a></li><li><a href=\"topic.htm?path=albendazole-patient-drug-information\" class=\"drug drug_patient\">Albendazole: Patient drug information</a></li></ul></div></div>","javascript":null}